PAR
Par Drugs And Chemicals financials
- Market cap
- ₹173 Cr
- Sector
- Healthcare
What Par Drugs And Chemicals Limited does
Par Drugs and Chemicals Limited manufactures Active Pharmaceutical Ingredients (APIs) and Fine Chemicals from a single site at Chitra, Bhavnagar (Gujarat), producing the full range of antacid-segment molecules (e.g., Magnesium Hydroxide, Sucralfate, Magnesium Trisilicate) along with industrial fine chemicals used in ceramics, agrochemicals and detergents. It sells both domestically and to roughly 16 export markets through a network of dealers and agents. Following shareholder approval at an Extraordinary General Meeting on 12 February 2025, the company has decided to exit its existing pharmaceutical and chemical operations and diversify into real estate & construction, capital markets, and clean & renewable energy.
Segments
- API (Active Pharmaceutical Ingredients)
- Fine Chemicals
- Manufacturing facility
- 1 site (Chitra, Bhavnagar, Gujarat) with 4 dedicated manufacturing blocks
- Installed capacity
- ~9,700 MTPA
- Product portfolio
- 15 APIs + 10 Fine Chemicals (25 products)
- Customer base
- 260+ customers (FY23)
- Dealer network (India)
- 40+ dealers (FY23)
- Agent network (global)
- 13+ agents (FY23)
Quarterly results
Q1 FY27: revenue up 20.1%, net profit up 41.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 35 | 21 | 22 | 26 | 29 −17% | 29 +37% | 20 −12% | 31 +20% |
| EBITDA | 11 | 1 | 2 | 4 | 6 −47% | 6 +323% | 1 −41% | 6 +79% |
| Net profit | 9 | 1 | 2 | 3 | 4 −52% | 5 +728% | 1 −48% | 5 +41% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +24.2% 1Y
1Y: ₹113.5 on 10 Sept 2025 → ₹140.92. High ₹168.25 (2 Sept 2026), low ₹78.58 (30 Mar 2026).
Financials, as filed
Revenue grew 4.1% a year over 2 years, FY24 to FY26. Operating margin narrowed to 16.5%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹96 Cr | ₹101 Cr | ₹104 Cr |
| Operating profit | ₹23 Cr | ₹20 Cr | ₹17 Cr |
| Operating margin | 23.9% | 19.3% | 16.5% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹3 Cr | ₹4 Cr | ₹4 Cr |
| Net profit | ₹15 Cr | ₹13 Cr | ₹13 Cr |
| Net margin | 15.2% | 13.2% | 12.6% |
| Cash from operations | ₹20 Cr | ₹16 Cr | ₹16 Cr |
| Free cash flow | ₹14 Cr | ₹15 Cr | ₹14 Cr |
| ROCE | 25.0% | 18.0% | 15.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹6 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr |
| Reserves | ₹46 Cr | ₹48 Cr | ₹59 Cr | ₹73 Cr | ₹94 Cr | ₹100 Cr |
| Borrowings | ₹8 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other liabilities | ₹16 Cr | ₹19 Cr | ₹18 Cr | ₹16 Cr | ₹21 Cr | ₹17 Cr |
| Total liabilities | ₹76 Cr | ₹79 Cr | ₹89 Cr | ₹102 Cr | ₹128 Cr | ₹129 Cr |
| Fixed assets | ₹30 Cr | ₹34 Cr | ₹38 Cr | ₹41 Cr | ₹38 Cr | ₹36 Cr |
| Capital work in progress | ₹5 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹27 Cr | ₹27 Cr |
| Other assets | ₹42 Cr | ₹44 Cr | ₹50 Cr | ₹60 Cr | ₹63 Cr | ₹65 Cr |
| Total assets | ₹76 Cr | ₹79 Cr | ₹89 Cr | ₹102 Cr | ₹128 Cr | ₹129 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public trimmed −0.12 pp. The shareholder count shrank 14% to 12,782.
- Promoters
- 73.4%
- DIIs
- 0.1%
- Public
- 26.5%
Since Jun 2025
- Public −0.12 pp
- DIIs +0.09 pp
- Promoters +0.04 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 74.2%, Public 25.8%.Dec '23: Promoters 74.2%, FIIs 0.1%, Public 25.7%.Mar '24: Promoters 74.2%, FIIs 0.1%, DIIs 0.1%, Public 25.7%.Jun '24: Promoters 74.2%, FIIs 0.3%, Public 25.5%.Sep '24: Promoters 73.4%, FIIs 0.1%, Public 26.5%.Dec '24: Promoters 73.4%, Public 26.6%.Mar '25: Promoters 73.4%, Public 26.6%.Jun '25: Promoters 73.4%, Public 26.6%.Sep '25: Promoters 73.4%, Public 26.6%.Dec '25: Promoters 73.4%, Public 26.6%.Mar '26: Promoters 73.4%, Public 26.6%.Jun '26: Promoters 73.4%, DIIs 0.1%, Public 26.5%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Par Drugs And Chemicals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Jignesh Vallabhbhai Savani | 21.88% | unchanged |
| Falgun Vallabhbhai Savani | 21.50% | unchanged |
| Saritaben Vallabhbhai Savani | 20.52% | unchanged |
| Ghanshayambhai B Savani | 6.52% | unchanged |
| Econo Trading And Investment Private Limited | 1.80% | unchanged |
| Savani Nayna Jignesh | 1.54% | unchanged |
| Shilpaben Falgun Savani | 1.44% | unchanged |
| Rakesh Balubhai Padariya (HUF) | 0.00% | unchanged |
| Sudha Shirish Padhye | 0.00% | unchanged |
| Aayush Jigneshbhai Savani | 0.00% | unchanged |
| Jinen Jigneshbhai Savani | 0.00% | unchanged |
| Dhiraj Govindbhai Tarpara | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- A decline
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse Par Drugs And Chemicals Limited
Guides on how to read this kind of business and the numbers that matter.